---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009564"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:48:17.537337+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics sells PRV for $155M cash; expects profitability early 2026

## Summary
- Definitive agreement to sell Rare Pediatric Disease PRV for $155M in gross cash proceeds at closing.
- PRV awarded by FDA on April 28, 2025 upon approval of ZEVASKYN (prademagene zamikeracel) for RDEB.
- CFO: proceeds provide over two years of operating expenses without additional financing; ZEVASKYN launch Q3 2025.
- Expects profitability in early 2026; closing subject to HSR waiting period; Stifel and Jefferies as advisors.

## SEC filing metadata
- accession: 0001641172-25-009564
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/0001641172-25-009564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009564
- JSON: https://secwatch.observer/filing/0001641172-25-009564.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.